MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
International Working Group for the Prognosis of MDS (IWG-PM)

The International Working Group for Prognosis in MDS (IWG-PM) consists of a group of international investigators aligned through the MDS Foundation whose focus is aimed at defining the clinical and biologic features of MDS thus providing the foundation for understanding the nature and potential for progression of this spectrum of disorders. To this end the group has generated programs leading to seminal projects and publications characterizing and classifying the disease. Current group investigations include determining the impact of mutational features that further delineate disease status and potential therapeutic targets providing novel treatment approaches for MDS.

MDS Risk Assessment Calculator

The IWG-PM under the aegis of the MDS Foundation, Inc. developed a prognostic tool, the IPSS-R Calculator, to determine a patient’s risk of progressing to Acute Myeloid Leukemia (AML).

Google Play Store

Click here to download the MDS IPSS-R Calculator app

Apple Store

Click here to download the MDS IPSS-R Calculator app

Click here to view members

Name Country
Lionel Ades France
Aref Al-Kali USA
Rafael Bejar* USA
Monika Belicková Czech Republic
John Bennett USA
Jacki Boultwood United Kingdom
David Bowen United Kingdom
Catherine Cargo United Kingdom
Mario Cazzola* Italy
Jaroslav Cermak Czech Republic
Jose Cervera Spain
Jane Churpek USA
Daniela Cilloni Italy
Maria Creignou Sweden
Matteo Giovanni Della Porta Italy
Nancy DiFronzo USA
Ben Ebert* USA
Pierre Fenaux France
Maria (Ken) Figueroa USA
Carlo Finelli Italy
Christa Fonatsch Austria
Michaela Fontenay France
Christina Ganster Germany
Guillermo Garcia-Manero USA
Norbert Gatterman Germany
Ulrich Germing Germany
Tim Graubert USA
Peter Greenberg* USA
Detlef Haase* Germany
Torsten Haferlach Germany
Rob Hasserjian USA
Eva Hellström Lindberg* Sweden
Anthony Hunter USA
Martin Jadersten Sweden
Joop Jansen The Netherlands
Aly Karsan Canada
Wolfgang Kern Germany
Virginia Klimek USA
Ioannis Kotsianidis Greece
Andrea Kuendgen Germany
Sandy Kurtin USA
Michael Lauseker Germany
Michelle Le Beau USA
Coleman Lindsley USA
Michael Luebbert Germany
Sigrid Machherndl-Spandl Austria
Jaroslaw Maciejewski USA
Silvia Magalhaes Brazil
Luca Malcovati* Italy
Mar Mallo Spain
Yashushi Miyazaki Japan
Ghulum Mufti United Kingdom
Kathrin Nachtkamp Germany
Donna Neuberg USA
Meritxell Nomdedeu Spain
Seishi Ogawa* Japan
Esther Oliva Italy
Eric Padron USA
Elli Papaemmanuel* USA
Andrea Pellagatti United Kingdom
Michael Pfeilstoecker Austria
Ronald Pinheiro Brazil
Uwe Platzbecker Germany
Lisa Pleyer Austria
David Sallman USA
Valeria Santini Italy
Fabio Santos Brazil
Guillermo Sanz Spain
Michael Savona USA
Julie Schanz Germany
Mikkael Sekeres USA
Lee-Yung Shih Taiwan
Francesc Sole Spain
Reinhard Stauder Austria
Kristen Stevenson USA
Lionel Ades France
Sudhir Tauro United Kingdom
Felicitas Thol Germany
Heinz Tuechler Austria
Johanna Ungerstedt Sweden
David Valcarcel Spain
Peter Valent Austria
Arjan van de Loosdrecht* The Netherlands
Norbert Vey France
Maria Theresa Voso Italy
Matt Walter USA
Amer Zeidan USA

*Coordinating Committee Member

Project: Clinical characterization/classification of MDS

Clinical characterization/classification of MDS – an international group of researchers involved in patient classification, stratification, and prognosis to refine the currently accepted and utilized prognostic scoring systems (IPSS, WPSS) and propose prognostic scoring systems into an improved internationally accepted system.

Publications

  1. Greenberg PL, Tuechler H, Schanz J, Sanz G, et al. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes. Blood 120: 2454-2465, 2012.
  2. Della Porta M, Tuechler H, Malcovati L, Schanz J, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 29: 1502-1513, 2015.
  3. Pfeilstoecker M, Tuechler H, Schanz J, Sanz G, et al. Time-Dependent Changes in Mortality and Transformation Risk in Myelodysplastic Syndromes. Blood 128: 902-910, 2016.
  4. Miyazaki Y, Tuechler H, Sanz G, Schanz J, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research 73: 51-57, 2018.
  5. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero, G, et al. Therapy-related Myelodysplastic Syndromes deserve specific diagnostic sub-classification and risk-stratification – An approach to classification of patients with t-MDS. Leukemia 2020, in press.
  6. Nomdedeu M, Tuechler H, Kuendgen A, et al. Cytogenetic findings in therapy-related MDS – relation with primary disease and therapy. Proc MDS Foundation Symposium, Copenhagen, May 2019.

Project:  Molecular classification of MDS Subtypes—Retrospective analysis

Molecular classification of MDS Subtypes – the development of a comprehensive risk algorithm that considers the composite molecular and clinical parameters that define a patient’s disease to capture more accurately patients with higher risk disease early; identify molecular patient subgroups that benefit from specific therapeutic intervention strategies (i.e hypomethylating agents) and thus deliver more effective treatment options in MDS – Retrospective analysis

Publications

  1. Haase DT, Stevenson K, Neuberg D, Maciejewski J, et al. TP53 Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Risk Groups. Leukemia 33:1747-1758, 2019.
  2. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, et al.  SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype – A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood 2020, in press.

Project:  IWG-PM/Molecular Project: Molecular/Clinical classification of MDS—Prospective analysis

Molecular classification of MDS Subtypes – the development of a comprehensive risk algorithm that considers the composite molecular and clinical parameters that define a patient’s disease to capture more accurately patients with higher risk disease early; identify molecular patient subgroups that benefit from specific therapeutic intervention strategies (i.e hypomethylating agents) and thus deliver more effective treatment options in MDS – Prospective analysis

Coordinating Committee: Elli Papaemmanuil, Ben Ebert, Rafael Bejar, Peter Greenberg

Oversight Steering Committee: Ben Ebert, Peter Greenberg, Elli Papaemmanuil, Rafael Bejar, Mario Cazzola, Luca Malcovati, Detlef Haase, Joop Jansen, Torsten Haferlach, Eva Hellstrom-Lindberg, Seishi Ogawa, Arjan van de Loosdrecht, Robert Hasserjian

Publications

  1. Bernard E, Nannya Y, Hasserjian R, Devlin S, Tuechler H, et al. Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes in press.
  2. Papaemmanuil E, Bernard, et al. Classification and personalized prognosis in MDS. MDS Foundation Symposium, ASH meeting, 2019 Orlando, December.
Review answers to commonly asked questions or get answers to your questions from an MDS expert